Health
Eli Lilly Acquires AtaiBeckley for Psychedelics Pipeline Expansion
Eli Lilly is acquiring the psychedelics-focused biotech company AtaiBeckley for $2.8 billion, aiming to expand its neuroscience research and development.
Coverage timeline — 1 article
STAT News
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.
2026-07-16 11:28 UTC